6 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | — | -$38M | — | — | -$39M | — | $120M |
| 2024 | — | -$55M | — | — | -$27M | $12M | $103M |
| 2023 | — | -$38M | — | — | -$35M | $21M | $35M |
| 2022 | $125000 | -$19M | 0.0% | -27777.6% | -$33M | — | $70M |
| 2021 | $125000 | -$36M | 0.0% | -20580.8% | -$24M | $560000 | $83M |
| 2020 | $125000 | -$18M | 0.0% | -11048.0% | -$11M | $483000 | $35M |
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | — | -$9M | — | — | -$19M | — | $195M |
| Dec '25 | — | -$29M | — | — | -$11M | — | $120M |
| Sep '25 | — | -$11M | — | — | -$10M | — | $87M |
| Jun '25 | — | -$5M | — | — | -$9M | — | $101M |
| Mar '25 | — | $7M | — | — | -$9M | — | $92M |
| Dec '24 | — | -$14M | — | — | -$6M | $12M | $103M |
| Sep '24 | — | -$11M | — | — | -$7M | $14M | $17M |
| Jun '24 | — | -$22M | — | — | -$6M | $17M | $21M |
| Mar '24 | — | -$8M | — | — | -$8M | $19M | $26M |
| Dec '23 | — | -$11M | — | — | -$7M | $21M | $35M |
| Sep '23 | — | -$8M | — | — | -$9M | $20M | $43M |
| Jun '23 | — | -$10M | — | — | -$7M | $20M | $52M |
| Mar '23 | — | -$9M | — | — | -$11M | $20M | $59M |
| Dec '22 | $31000 | -$5M | 0.0% | -26132.3% | -$7M | — | $70M |
| Sep '22 | $31000 | -$9M | 0.0% | -28648.4% | -$10M | — | $77M |
| Jun '22 | $31000 | -$4M | 0.0% | -28235.5% | -$8M | — | $87M |
| Mar '22 | $31000 | -$874000 | 0.0% | -28987.1% | -$8M | — | $94M |
| Dec '21 | $31000 | $2M | 0.0% | -24967.7% | -$6M | $560000 | $83M |
| Sep '21 | $31000 | -$16M | 0.0% | -25900.0% | -$7M | $541000 | $88M |
| Jun '21 | $31000 | -$17M | 0.0% | -17100.0% | -$5M | $521000 | $24M |
How the market has priced CADL against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 5 years, Candel Therapeutics, Inc.'s revenue has grown 0.0% per year. These are computed facts, not advice.
As of FY2025, Candel Therapeutics, Inc. reported — of total debt against $120M of cash; operating income covered interest expense -22.8×.
In FY2025, gross margin was —, operating margin —, and net margin —.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.